NECTIN2 and prostate cancer: In prostate cancer, high expression of PVR receptors (CD155 and CD112) has been reported in patients with resistant and castration-sensitive prostate cancer; for this reason, these receptors were proposed as potential targets in prostate cancer [22, 23].